SG78239A1 - Angiogenesis inhibitory antibodies - Google Patents

Angiogenesis inhibitory antibodies

Info

Publication number
SG78239A1
SG78239A1 SG1996000859A SG1996000859A SG78239A1 SG 78239 A1 SG78239 A1 SG 78239A1 SG 1996000859 A SG1996000859 A SG 1996000859A SG 1996000859 A SG1996000859 A SG 1996000859A SG 78239 A1 SG78239 A1 SG 78239A1
Authority
SG
Singapore
Prior art keywords
pct
endothelial cells
angiogenesis
sec
inhibitory antibodies
Prior art date
Application number
SG1996000859A
Other languages
English (en)
Inventor
Christopher Richard Parish
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3776506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG78239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Australian filed Critical Univ Australian
Publication of SG78239A1 publication Critical patent/SG78239A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG1996000859A 1992-10-29 1993-10-29 Angiogenesis inhibitory antibodies SG78239A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPL557392 1992-10-29

Publications (1)

Publication Number Publication Date
SG78239A1 true SG78239A1 (en) 2001-02-20

Family

ID=3776506

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996000859A SG78239A1 (en) 1992-10-29 1993-10-29 Angiogenesis inhibitory antibodies

Country Status (9)

Country Link
US (2) US5677181A (fr)
EP (1) EP0669988B2 (fr)
JP (1) JP3490443B2 (fr)
AT (1) ATE250138T1 (fr)
AU (1) AU673865B2 (fr)
CA (1) CA2148244A1 (fr)
DE (1) DE69333209T2 (fr)
SG (1) SG78239A1 (fr)
WO (1) WO1994010331A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
SG78239A1 (en) * 1992-10-29 2001-02-20 Univ Australian Angiogenesis inhibitory antibodies
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
ES2188202T3 (es) 1998-07-13 2003-06-16 Univ Texas Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos.
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
WO2000002584A2 (fr) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Procedes de traitement du cancer reposant sur l'utilisation d'anticorps vis-a-vis des aminophospholipides
JP4926320B2 (ja) 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
EP2298334A3 (fr) * 1999-12-20 2012-04-04 Immunex Corporation Récepteur tweak
US6727192B2 (en) * 2001-03-01 2004-04-27 Micron Technology, Inc. Methods of metal doping a chalcogenide material
US20030139374A1 (en) * 2001-09-27 2003-07-24 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coagulation and treatment
CA2478317A1 (fr) * 2002-03-04 2003-09-18 Medimmune, Inc. Procedes permettant de prevenir ou de traiter des troubles par administration d'un antagoniste de l'integrine .alpha.v.beta.3 associe a un inhibiteur de la reductase hmg-coa ou unbisphosphonate
EP1487492A4 (fr) * 2002-03-04 2008-10-01 Medimmune Inc Prevention ou traitement de cancer au moyen d'antagonistes de l'integrine alphavbeta3 combines a d'autres agents
AU2003272449A1 (en) * 2002-09-16 2004-04-30 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
AU2004207002A1 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
EP1625165A2 (fr) * 2003-04-03 2006-02-15 Protein Design Labs, Inc. Procedes de production et utilisation d'anticorps anti-integrine permettant d'inhiber la granulation tissulaire
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
CA2530533C (fr) 2003-06-27 2015-02-10 Ethicon, Incorporated Cellules postnatales derivees de tissu de cordon ombilical, et leur procede de production et d'utilisation
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
AU2005322060B2 (en) 2003-06-27 2011-11-17 Ethicon Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US7662384B2 (en) * 2004-03-24 2010-02-16 Facet Biotech Corporation Use of anti-α5β1 antibodies to inhibit cancer cell proliferation
PL1819358T3 (pl) 2004-11-18 2015-02-27 Imclone Llc Przeciwciała przeciwko czynnikowi wzrostu śródbłonka naczyniowego
IL165365A0 (en) 2004-11-24 2006-01-15 Q Core Ltd Finger-type peristaltic pump
PL1835924T3 (pl) 2004-12-23 2014-01-31 Ethicon Incorporated Leczenie choroby Parkinsona i zaburzeń związanych z tą chorobą z użyciem komórek uzyskiwanych po porodzie
US9175261B2 (en) 2005-12-16 2015-11-03 DePuy Synthes Products, Inc. Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
JP5179376B2 (ja) 2005-12-19 2013-04-10 エシコン・インコーポレイテッド ローラーボトルでの分娩後取り出し細胞の体外増殖
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
WO2009018226A2 (fr) * 2007-07-27 2009-02-05 Facet Biotech Corporation Combinaisons pharmaceutiques
US8034329B2 (en) 2007-10-05 2011-10-11 Advanced Technologies And Regenerative Medicine, Llc Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
US10557116B2 (en) 2008-12-19 2020-02-11 DePuy Synthes Products, Inc. Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
SG174551A1 (en) 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
BR112014015424A2 (pt) 2011-12-23 2018-05-22 Depuy Synthes Products Llc detecção de células derivadas de tecido do cordão umbilical humano

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721672A (en) * 1985-08-28 1988-01-26 President And Fellows Of Harvard College CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression
US5512660A (en) * 1987-05-04 1996-04-30 Dana Farber Cancer Institute, Inc. Purified ICAM-2 and fragment thereof
AU2807189A (en) † 1987-11-19 1989-07-05 Scripps Clinic And Research Foundation Monoclonal antibody against the rgd-directed adhesion receptor of endothelial cells
ATE174223T1 (de) * 1989-04-10 1998-12-15 Oncogen Verwendung von oncostatin m zur suppression von mhc antigenen
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
IT1239065B (it) * 1990-05-14 1993-09-20 Fidia Spa Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
EP0505749A3 (en) * 1991-02-26 1993-06-23 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to activated endothelial cells and their therapeutic and diagnostic use
SG78239A1 (en) * 1992-10-29 2001-02-20 Univ Australian Angiogenesis inhibitory antibodies

Also Published As

Publication number Publication date
US5677181A (en) 1997-10-14
EP0669988B1 (fr) 2003-09-17
AU5366194A (en) 1994-05-24
US5874081A (en) 1999-02-23
JP3490443B2 (ja) 2004-01-26
JPH08502409A (ja) 1996-03-19
ATE250138T1 (de) 2003-10-15
EP0669988B2 (fr) 2009-07-08
EP0669988A4 (fr) 1996-07-31
AU673865B2 (en) 1996-11-28
DE69333209T2 (de) 2004-07-01
EP0669988A1 (fr) 1995-09-06
DE69333209D1 (de) 2003-10-23
WO1994010331A1 (fr) 1994-05-11
CA2148244A1 (fr) 1994-05-11

Similar Documents

Publication Publication Date Title
SG78239A1 (en) Angiogenesis inhibitory antibodies
Jiang et al. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets.
NO955029L (no) Intravaginalt avleveringssystem
CA2032123A1 (fr) Dispositif de renfort et de soutien de la coiffe des rotateurs d'une articulation d'epaule d'individus
DK151687D0 (da) Aprotinin-homologe fremstillet ud fra en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert derfor og farmaceutisk anvendelse deraf
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DK0592521T3 (da) Marv-afledte humane mesenchymal-stamceller og monoklonale antistoffer specifikke for nævnte celler
WO2000063246A3 (fr) Composes et procedes de modulation de l'expression genetique par l'intermediaire de la beta-catenine
DE68918944D1 (de) Künstliche rezeptor-analoge.
NZ290422A (en) Pyridyl or pyrimidinyl substituted thiopyridine derivatives and medicaments
GEP20002257B (en) Method for Reducing Fibrin Accumulation Speed, Prophylactics of Thrombus Complications and Treatment of Blood Vessels Diseases, Medicinal Composition and Medicinal Species
AU5810498A (en) Method and constructs for inhibiting protein expression in bacteria
ES2057572T3 (es) Agentes de reconocimiento.
ATE203674T1 (de) Verwendung eines extraktes von alchemilla vulgaris
ES2000615A6 (es) Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"
MX9700042A (es) Aislados de bacillus thurigiensis activo contra cucarachas.
NO951277L (no) Desulfatohirudin med höy molekylvekt
PL323195A1 (en) Alpha unit of human integrin beta 2
AU2002366739A8 (en) Apoptotically active peptides
ATE279521T1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
ITRM930280A0 (it) Contenitore per imballaggio di biancheria d'arredamento, intima e abbigliamento.
UA18224A (uk) Спосіб лікуваhhя дерматозів
IT1288184B1 (it) Procedimento per l'accorciamento del tempo di chiusura e dispositivo per l'attuazione del procedimento.
Remport Isothermal Growth of Austenite of Unalloyed Steels
HU9200336D0 (en) 2,4- and 2,5-bis-tetrazolyl-piridine-derivatives, process for their production and medical preparations containing them